112 related articles for article (PubMed ID: 37563858)
1. Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS-142 in healthy Japanese participants following single/multiple dosing: Randomized, double-blind, placebo-controlled phase-1 studies.
Kambe D; Hasegawa S; Imadera Y; Mano Y; Matsushita I; Konno Y; Ogo H; Uchimura N; Uchiyama M
Basic Clin Pharmacol Toxicol; 2023 Nov; 133(5):576-591. PubMed ID: 37563858
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Landry I; Nakai K; Ferry J; Aluri J; Hall N; Lalovic B; Moline ML
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):153-165. PubMed ID: 32468649
[TBL] [Abstract][Full Text] [Related]
3. Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia.
Konno Y; Kamigaso S; Toki H; Terasaka S; Hikichi H; Endo H; Yamaguchi JI; Mizuno-Yasuhira A
Pharmacol Res Perspect; 2024 Apr; 12(2):e1183. PubMed ID: 38491717
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration.
Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J
J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731
[TBL] [Abstract][Full Text] [Related]
5. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.
Muehlan C; Brooks S; Zuiker R; van Gerven J; Dingemanse J
Eur Neuropsychopharmacol; 2019 Jul; 29(7):847-857. PubMed ID: 31221502
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.
Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H
Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects.
Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G
J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006
[TBL] [Abstract][Full Text] [Related]
8. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
[TBL] [Abstract][Full Text] [Related]
9. Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects.
van der Ark PD; Golor G; van Nueten L; Nandy P; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1330-1340. PubMed ID: 30182786
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
Yang L; Shu P; Wu N; Hu M; Luo Z
Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Jansen M; Warrington S; Dishy V; Ohwada S; Johnson L; Brown K; Ishizuka H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):661-669. PubMed ID: 29663714
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults.
Berg AK; Myrvik MJ; Van Ess PJ
Epilepsy Behav; 2017 Jun; 71(Pt A):51-59. PubMed ID: 28544992
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
15. Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313.
Kaufmann P; Ort M; Golor G; Kornberger R; Dingemanse J
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110166. PubMed ID: 33159976
[TBL] [Abstract][Full Text] [Related]
16. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.
Desai A; Benner L; Wu R; Gertsik L; Uz T; Marek GJ; Zhu T
Clin Pharmacokinet; 2021 Jan; 60(1):79-88. PubMed ID: 32533536
[TBL] [Abstract][Full Text] [Related]
18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB; Berthelsen KK; Kankam M; Lund MT; Rubino DM; Satylganova A; Lau DCW
Lancet; 2021 May; 397(10286):1736-1748. PubMed ID: 33894838
[TBL] [Abstract][Full Text] [Related]
20. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Frost C; Wang J; Nepal S; Schuster A; Barrett YC; Mosqueda-Garcia R; Reeves RA; LaCreta F
Br J Clin Pharmacol; 2013 Feb; 75(2):476-87. PubMed ID: 22759198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]